The efficacy of human alpha interferon (IFN-a) combined with 9-(2'-hydroxyethoxymethyl)guanine (acyclovir; ACV), (E)-5-(2-bromovinyl)-2'-deoxyuridine, 9-0-D-arabinofuranosyladenine, or 1-0-D-arabinofuranosylcytosine on the inhibition of human cytomegalovirus (HCMV) replication in human embryonic lung cells was analyzed by plaque reduction assays. IFN-a combined with 9-,B-Darabinofuranosyladenine or 1-,B-D-arabinofuranosylcytosine produced an additive antiviral activity with respect to HCMV plaque formation. IFN-a combined with (E)-5-(2-bromovinyl)-2'-deoxyuridine also exhibited additive antiviral activity. However, IFN-a combined with ACV at concentrations higher than 10 ,uM consistently yielded synergistic activity in HCMV plaque reduction assays. Kinetic analyses of HCMV replication demonstrated that approximately a 1,000-fold reduction can be attained through the synergistic interaction between ACV (200 ,uM) and IFN-a (42 IU/ml). These data suggest that combined ACV and IFNa treatment may be useful against HCMV infection.
9-0-D-arabinofuranosyladenine, or 1-0-D-arabinofuranosylcytosine on the inhibition of human cytomegalovirus (HCMV) replication in human embryonic lung cells was analyzed by plaque reduction assays. IFN-a combined with 9-,B-Darabinofuranosyladenine or 1-,B-D-arabinofuranosylcytosine produced an additive antiviral activity with respect to HCMV plaque formation. IFN-a combined with (E)-5-(2-bromovinyl)-2'-deoxyuridine also exhibited additive antiviral activity. However, IFN-a combined with ACV at concentrations higher than 10 ,uM consistently yielded synergistic activity in HCMV plaque reduction assays. Kinetic analyses of HCMV replication demonstrated that approximately a 1,000-fold reduction can be attained through the synergistic interaction between ACV (200 ,uM) and IFN-a (42 IU/ml). These data suggest that combined ACV and IFNa treatment may be useful against HCMV infection.
Human cytomegalovirus (HCMV) has been implicated in a wide range of clinical diseases, including intrauterine infections, perinatal infections, infections of immunosuppressed transplant and cancer patients, birth defects, and, more recently, acquired immunodeficiency disease syndrome and Kaposi sarcoma (2, 14, 20, 24) . In general, treatment of HCMV with 1-P-Darabinofuranosylcytosine (ara-C [25] ), 9-P-Darabinofuranosyladenine (ara-A [19] ) or human alpha interferon (IFN-a [21] ) has not been successful. In addition, the newly licensed drug 9-(2'-hydroxyethoxymethyl)guanine (acyclovir; ACV) has not been effective in the treatment of HCMV pneumonia (32) .
Each of these compounds was initially shown to be an effective inhibitor of herpes simplex virus (HSV) and has been used to treat HSV infections (4, 5, 10, 13, 23) . However, due to problems of low therapeutic indices and isolation of HSV resistant to these antiviral agents, studies have been undertaken to examine the potential of polychemotherapy in the treatment of HSV infections. Combination therapy has proven to be effective against bacterial infections and certain cancers (9, 26) and may allow decreased dosage and duration of treatment, thus reducing toxicity and the incidence of resistant virus strains.
Numerous in vitro studies have examined the type of interaction (additive, synergistic, or antagonistic) of various antiherpetic compounds when used in combination. Ara-A in combination with human beta interferon (IFN-P [3] ) or ACV (27) has been shown to have an additive inhibitory effect on HSV replication. Synergistic inhibitory interactions have been reported with ara-A in combination with IFN-a (16) or (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU [27] ). ACV combined with IFN-a (17) or IFN-t3 (29) has also been shown to have a synergistic inhibitory effect on HSV replication. However, the combined interaction of ACV with BVDU has been shown to be only additive (27) . ACV in combination with BVDU has also been demonstrated to have only an additive inhibitory effect on the replication of varicella-zoster virus (1) . In addition, the anti-varicella-zoster virus effect of ACV combined with trifluorothymidine has been shown to be additive. However, ACV in combination with ara-A has been shown to have additive to synergistic inhibitory effects on varicella-zoster virus replication (1) .
Similar studies have been performed with HCMV, the majority of which examined ACV in combination with other antiviral agents. The anti-HCMV effect of ACV combined with IFN-a (17) or IFN-P (28) has been demonstrated to be additive and, depending on the HCMV strain, to be additive to synergistic when combined with phosphonoformic acid or trifluorothymidine (28) . Although BVDU is an effective inhibitor of HSV and is relatively noncytotoxic (8) , few studies have tested the effect of BVDU on 326 SMITH, WIGDAHL, AND RAPP HCMV replication when used in polychemotherapeutic regimens.
These studies were undertaken to further examine the type of interactions involved in combination chemotherapy of HCMV-infected cells. Reports that ACV in combination with human IFNs produces at least additive inhibitory effects on HCMV replication (17, 28) prompted our investigation of the combined use of ACV and IFN-a in plaque reduction and replication kinetic assays. Since ara-A combined with IFNa or BVDU has been shown to act in a synergistic manner to inhibit HSV (16, 27) were grown in Dulbecco medium containing 10%o heatinactivated fetal calf serum as previously described (6, 7, 30) . Maintenance medium contained 5% fetal calf serum with supplements as previously described (6, 7) . HCMV strain AD169 was obtained from the American Type Culture Collection, Rockville, Md. The virus was plaque purified, and stocks were prepared and titrated in HEL cells as previously described (6, 30) . Antiviral agents. Ara-C and ara-A were purchased from Sigma Chemical Co., St the cultures were overlaid with 2 ml of 0.3% agarose medium supplemented with 5% fetal calf serum and no inhibitors, with IFN-a alone, or with ara-A, ara-C, ACV, or BVDU alone or in combination with IFN-a as previously described (33) . The cultures were then incubated at 37°C, and every 72 h, 1.0 ml offresh 0.3% agarose medium containing the appropriate concentration of the nucleoside analog was added. After incubation at 37°C for 10 days, the infected cultures were fixed with 5% Formalin in phosphate-buffered saline and stained with methylene blue. Discrete foci were counted under a dissecting microscope. The mean plaque number was calculated from quadruple samples and converted to a percentage of untreated controls.
Kinetic analysis of HCMV replcton. Approximately 2.3 x 105 HEL cells were seeded in 35-mm plates, incubated for 24 h at 37°C, and infected with HCMV at a multiplicity of infection (MOI) of 3. After a 2-h adsorption period at 37°C, the cultures were washed twice with phosphate-buffered saline; overlaid with 3 ml of maintenance medium containing no inhibitors, IFN-a alone, ACV alone, or ACV in combination with IFN-a; and incubated at 37°C. At 72-h intervals, 1 ml of medium with or without ACV was added to the remaining cultures. Triplicate samples were frozen after adsorption and at 24-h intervals and then stored at -70°C until the infectious virus content of each culture was determined.
The total virus content of each culture was determined as previously described (6, 30) with several modifications. Briefly, the cultures were frozen and thawed three times and sonicated, and cell debris was eliminated by centrifugation at 1,000 x g for 10 min. The infectious virus was quantitated by plaque assay in HEL cells (30) . The mean total virus content of the cultures was calculated and converted to a percentage of untreated controls. combinations. The numerical result of this final equation is defined as the combination index (CI). When In(AB) decreases, the CI increases and approaches synergism. However, if ln(AB) increases, the CI decreases and approaches antagonism. The activity of two antiviral agents is defined as additive if the CI is within two standard errors (SE) of zero (0 + 2 SE . CI -0 -2 SE), as synergistic if the CI is more than two SE greater than zero (CI > 0 + 2 SE), or as antagonistic if the CI is more than two SE less than zero (CI < 0 -2 SE). Representative analyses of three growth ki- (Table 3) . Plaque reduction assays indicated that the additive interaction of ACV and IFN-a could be changed to a synergistic interaction by increasing the concentration of ACV. Therefore, the effect of increased concentrations of ACV and IFN-a (100 F,M and 42 IU/ml, respectively) on HCMV replication was determined. The virus yield in cultures treated with both agents at these increased concentrations resulted in approximately a 20-fold increase in the inhibition of HCMV replication relative to that observed with 20 F*M ACV and 16 IU of IFN-a per ml during days 3 to 5 postinfection (Fig. 2) . Thus, the replication of HCMV in HEL cells treated with 100 ,M ACV and 42 IU of IFN-a per ml was approximately 1% of the untreated control cells. Depending on the time postinfection, the degree of inhibition of HCMV replication was the result of an additive to synergistic interaction between ACV and IFN-a (Table 3) .
RESULTS
A comparison of the HCMV replication kinetics ( Fig. 1 and 2) shows that increasing the concentration of IFN-a alone from 16 to 42 IU/ml had little or no effect on the degree of inhibition observed and that a maximal effect appeared to be attained at concentrations of between 16 and 42 IU/ml. Increasing the ACV concentration from 20 to 100 ,uM greatly decreased the HCMV yield in infected cells treated with ACV alone. However, the anti-HCMV effect of 42 IU of IFN-a per ml combined with 100 pM ACV fluctuated between additive and synergistic on each day during the exponential phase of the replication cycle. Subsequently, ANTIMICROB. AGENTS CHEMOTHER. As shown in Fig. 3, 200 ,uM ACV in combination with 42 IU of IFN-a per ml resulted in extensive inhibition of HCMV replication during days 3 to 5 postinfection. Relative to untreated control culture, HCMV titers in cells treated with ACV and IFN-a were approximately 3 logs lower. In each of three experiments, this greater inhibition was the result of synergistic interaction between ACV and IFN-a throughout the replication cycle (Table 3 ) and was not due to drug cytotoxicity. Both trypan blue dye exclusion and plating efficiency studies demonstrated that ACV (200 piM) and IFN-a (42 IU/ml) in combination were relatively noncytotoxic to HEL cells incubated over a 6-day period under these experimental conditions. virus content in triplicate samples was determined, HCMV has been shown to be several times more and the average value was plotted, resistant than HSV to antiherpes agents such as ACV and trifluorothymidine (15, 31) . The experiments reported here were designed to test growth studies were performed at an increased whether IFN-a in combination with nucleosides concentration of ACV (200 ,uM) combined with demonstrated synergistic antiviral effects on the the same concentration of IFN-a (42 IU/ml) to replication of HCMV. determine whether an increased inhibition of Our results demonstrate that IFN-a combined with ara-A or ara-C at all concentrations tested had additive alivimrl effects, resulting in a maximum of 80% HCMV plaque reduction relative to controls. Higher concentrations of these agents in combination were cytotoxic and could not be examined. These results indicate that IEN-a combined with ara-A or ara-C would not be useful as a synergistic combination treatment of HCMV infection.
Examination of BVDU inhibition of HCMV demonstrated that, when used as a single agent, 10 FiM was required for 50% plaque reduction (data not shown). Therefore, the sensitivity of HCMV to BVDU was approximately 3-or 300-fold less than the sensitivity reported iXor HSV-2 or HSV-1, respectively, but 30-fold greater than that reported for thymidine kinase-deficient HSV type 1 (8) . In general, BVDU antiviral interactions with IFN-a were additive, resulting in 70 to 85% inhibition of HCMV plaque formation. These results do not preclude a possible synergistic interaction between BVDU and IFNa at higher noncytotoxic concentrations. We did not pursue this possibility because the efficacy of combined ACV and IFN-a appeared to be greater in the plaque reduction analyses. The exact mechanism by which ACV inhibits HCMV replication is unknown. Elion et al. (12) have demonstrated that the high potency and selectivity of ACV for HSV are due to the ability of these viruses to code for a viral thymidine kinase which has the capability to phosphorylate ACV to the nucleoside monophosphate, whereas cellular thymidine kinase does not have this capability. For HCMV, which does not specify its own thymidine kinase (22, 34), the amount of ACV phosphorylated in infected cells is low (11) . However, the HCMV polymerase is 10 times more sensitive than the cellular DNA polymerase to inhibition by the nucleoside 5'-triphosphate (11) which may contribute to inhibition of HCMV by ACV at noncytotoxic concentrations. In addition, ACV may inhibit HCMV by exerting a transient inhibition of the synthesis of two virus-specific late polypeptides (18) .
The synergistic effect of ACV and IFN-a on HCMV may represent the combination of effects on two or more different pathways of viral inhibition. IFN appears to inhibit virus replication at the level of translation but does not seem to have a direct effect on viral DNA polymerase. Therefore, the synergistic antiviral effect of ACV combined with IFN-a may include the inhibition of HCMV at the level of both viral DNA replication and transcription.
These studies indicate that both the combined drug concentrations and the method of assay are important factors in determining whether agents have potential synergistic polychemotherapeutic value. Results obtained from investigations of combination treatment of in vitro HCMV infection suggest that at high but therapeutically attainable and tolerated levels in humans (21, 32) , ACV combined with IFN-a warrants further examination as a treatment for clinical HCMV infection.
